期刊文献+

左乙拉西坦中间体LV30合成工艺的开发和优化研究

Developing and Optimizing the Synthesis Technology of an Intermediate of Levetiracetam( LV30)
下载PDF
导出
摘要 一种左乙拉西坦(levetiracetam)中间体LV30的制备方法,以甲苯、甲醇为溶剂、以氢化钠为甲基化试剂,调整反应条件找出最佳配比,使2-吡咯烷酮与溴丁酸甲酯反应,然后经碱水解和盐酸酸化制得LV30的外混旋体:(±)-α-乙基-(2氧-1-吡咯烷基)乙酸(LV20),LV20再通过和苯乙胺与其成盐,拆分制得左旋体(S)-α-乙基-2-氧-1-吡咯烷乙酸,-苯乙胺盐(LV30)。本发明工艺LV30收率达到40%以上,工艺简单,便于操作,产品光学纯度大于99%。 This research is about a process method of LV30,an intermediate of levetiracetam. Taking toluene and methanol as solvent,sodium hydride as methylating reagent,an optimum proportion is gained by adjusting reaction conditions. During this process,2-pyrrolidone methylation reagent reacts with methyl 2-bromobutyrate at first. Then the compound is processed through basic hydrolysis and hydrochloric acidizing to get LV20,the ex-mix optical active substance of LV30. LV30,the levo form,is obtained after LV20 is salified with phenyletheylamine and split. Applying this technology,which is simple and easy to handle,the yield of LV30 is above 35% and the optical purity of products is over 99%.
作者 刘晓光 张存莉 王俊臣 杨秋燕 武志刚 Liu Xiaoguang Zhang Cunli Wang Junchen Yang Qiuyan Wu Zhigang(Northwest Agriculture and Forestry University, Yarding 712100,China Topfond Phamaeeuticals Company Limited, Zhumadian 463000,China)
出处 《山东化工》 CAS 2016年第19期6-7,共2页 Shandong Chemical Industry
关键词 左乙拉西坦 LV30 甲苯 氢化锂 levetiracetam LV30 methylbenzene sodium hydride
  • 相关文献

参考文献4

二级参考文献13

  • 1黄铁栓,朱金兰,李冰,胡雁,廖建湘.抗癫痫药物加重儿童癫痫发作的临床研究[J].中国当代儿科杂志,2004,6(5):401-402. 被引量:8
  • 2吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 3Mukta D, Greg L P. Levetiracetam: A Review of its Adjunctive Use in the Management of Partial Onset Weizures[J]. Drugs, 2000, 60 (4): 871 -893.
  • 4Alma J G, Michel N. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals[J]. Eru J pharmacol, 1992,222:193-203.
  • 5Jean G, Jean-Pierre G, Guy B. (S)- Alpha- Ethyl-2- oxo-1- Pyrrolidineacetamide[P].US:4696943,1987-9-29.
  • 6Eric C, Genevieve M, Jean-Pierre G, et al. The preparation of (S)-Alpha-Ethyl-2-oxo-1-Pyrrolidineacetamide[P]. GB:2225322,1990-5-30.
  • 7Tooru F, Jean-Pierre C, Emile C, et al. Process for the preparation of levetiracetam[P].US:6107492,2000-8-22.
  • 8Surtees J, Marmon V, Differding E, et al. 2-Oxo-1-pyrroliding derivatives, process for preparing them and their uses[P].WO:0164637 A1, 2001-9-7.
  • 9Ates C, Surtees J, Burteau A-C, et al. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues[P].WO:03014080 A2,2003-2-20.
  • 10Tim D,Robtecht R,Kristl V,et al.Levetiracetam:Part Ⅱ,the Clinical profile of a Novel Anticonvulsant Drug[J].CNS Drug Rev,2007,13(1):57-58.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部